This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.
NICE has produced a COVID-19 rapid guideline on dermatological conditions treated with drugs affecting the immune response. It recommends changes to usual practice to maximise the safety of patients and protect staff from infection during the COVID-19 pandemic.
In September 2017, we revised the guideline throughout to link to other NICE guidance (including technology appraisals) and some relevant non-NICE guidelines, as well as including new MHRA safety advice and updated licensing information.
This guideline includes recommendations on:
- principles of care
- assessment and referral
- topical therapy
- phototherapy (broad- or narrow-band narrowband ultraviolet B light and psoralen with local ultraviolet A)
- systemic therapy
Who is it for?
- Healthcare professionals
- Commissioners and providers
- Children and adults with a diagnosis of psoriasis, and their families and carers
Is this guideline up to date?
We checked this guideline in June 2017. We found no new evidence that affects the recommendations in this guideline.
Guideline development process
This guideline was previously called psoriasis: the assessment and management of psoriasis.
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.